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Abstract
The cytokines tumor necrosis factor-a (TNF-a) and its soluble TNF receptors 
55 and 75 (sTNFR5 5, sTNFR75), interleukin-1 p (IL-1|3) and interleukin-6 
(IL-6) were measured in plasma from 13 patients with the hemolytic uremic 
syndrome (HUS) on admission. No significant changes in the plasma levels of 
TNF-a and IL-lp were detected in the HUS patients as compared to the plas­
ma levels of the control groups. Levels of IL-6 were significantly elevated in 
the plasma of those HUS patients who had extrarenal manifestations, consist­
ing of seizures, loss of consciousness, coma and pancreatic necrosis. Although 
the exact function of IL-6 in the plasma of HUS patients is still unknown and 
the group of HUS patients is small, plasma IL-6 is associated with the severity 
and outcome of the disease. Plasma levels of sTNR55 and sTNFR75 were 
significantly elevated in all HUS patients compared to the healthy controls, 
but they were also elevated in the children with chronic renal failure. This 
indicates that elevated levels of circulating sTNFR should be carefully inter­
preted when kidney failure exists.
Introduction
Hemolytic uremic syndrome (HUS) is characterized 
by hemolytic anemia, thrombocytopenia and acute renal 
failure. The most common form of HUS seen in children 
is the epidemic form, which is preceded by an acute, often 
bloody, gastroenteritis [1]. In the last decade it has 
become clear that infections with verocytotoxin-produc- 
ing Escherichia coli strains are the main cause of HUS in 
childhood [2, 3]. Although the exact pathogenesis of HUS 
is still unknown, it is generally accepted that endothelial 
cell activation and damage play a central role. Cytokines 
such as tumor necrosis factor-a (TNF-a), interleukin-1 (3 
(IL-lp) and interleukin-6 (IL-6) are known to play an
important role in infectious and inflammatory diseases, 
and have been extensively studied in diseases such as sep­
sis, severe infectious purpura and Kawasaki disease [4-6]. 
Elevated levels of cytokines are also found in plasma tak­
en in the acute phase of patients with thrombotic throm­
bocytopenic purpura (TTP), a syndrome which is in many 
aspects familiar with HUS [7].
The aim of this study was to determine whether circu­
lating cytokines are detectable in the blood of HUS 
patients. For this purpose, we measured TNF-a and its 
soluble receptors sTNFR55 and sTNFR75, IU-ip and IL- 
6 in the plasma of 13 patients admitted to the hospital 
with the epidemic form of HUS.
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Table 1. Laboratory indices of patients 
with HUS on the day of admission Patient
No.
Age
months
Hb
mmol/1
Platelets
109/I
WBC
109/1
Urea
mmol/1
Creatinine
jxmol/l
1 14 3.9 276 22.3 20.2 106
2 21 4.9 45 20.4 33 295
3 6 4.7 25 25.5 29.6 350
4 53 5.3 56 31.5 36 770
5 112 5.5 55 10.9 67 1,020
6 36 4.2 138 17.7 40 640
7 54 3.7 203 8.8 63.2 928
8 10 4.1 56 23.2 61.6 514
9 41 3.7 130 12 45 178
10 22 3.9 37 19.5 26.9 288
11 36 9.2 304 24.1 6.8 54
12 22 7.5 11 53.6 68.2 335
13 40 5.7 30 33.6 17.2 157
Normal values children 6—9 140-440 4-1 i 3-7 30-90
The laboratory indexes are given for each HUS patient. On the second day after admis­
sion the laboratory parameters of patient 11 were as follows: Hb 4.5 mmol/1, platelets 25 x 
109/1, urea 10,5 mmol/1 and creatinine 130 jxmol/1. Patients 10,11,12 and 13 had, in contrast 
with the other HUS patients, severe extrarenal manifestations, consisting of seizures, loss of 
consciousness, and coma. Pancreatic necrosis was also diagnosed in patient 10.
Patients and Methods
Patients
Thirteen children (4 females/9 males, mean age 38 ± 28 months; 
range 6-112  months) were diagnosed as having HUS, because of the 
presence of hemolytic anemia with burr cells in the peripheral blood 
smear, renal failure and thrombocytopenia [8], HUS was preceded 
by mostly blood-stained diarrhea. Antibodies against the most com­
mon verocytotoxin-producing E. coli (VTEC) serotype 0157, which 
indicates an infection with VTEC, were detected in the plasma of 7 of 
12 patients [9].
The main laboratory indexes of the patients on admission are dis­
played in table 1. On the day of admission to the hospital, before any 
treatment was given, blood from these 13 children was collected into 
EDTA-containing tubes, centrifuged and the plasma was stored in 
small aliquots at -70  °C until assays were performed. Plasma of 8 
age-matched healthy children and 8 children with chronic renal fail­
ure taken before dialysis served as controls.
Methods
TNF-a was assessed by radioimmunoassay (RIA), as previously 
described [10]. This RIA measures total TNF-a (both free and com- 
plexed to its receptors), as demonstrated by the lack of interference of 
the addition of up to 5 ng/ml recombinant sTNFR55 and sTNFR75 
to sera containing known amounts of TNF-a. The sensitivity of this 
assay is 100 pg/ml. IL-ip assay was also performed with a RIA [11]. 
Before application, both RIAs (TNF-a and IL- 1 (3) were thoroughly 
validated towards linearity and determination of matrix effects. 
When 100 jxl of plasma was tested, recovery experiments of the 
respective cytokine resulted in recovery values exceeding 90%, both 
at the low and the high concentration range tested. IL-6 was mea­
sured by an ELISA as described by Barrera et al. [12]; materials were 
a gift from Dr. J. Wijdenes (Innotherapy, Besançon, France). The 
sensitivity of this ELISA is 20 pg/ml.
Soluble TNF receptors (sTNFR5 5 and sTNFR7 5 ) were measured 
by ELISA (Hoffmann-La Roche, Basel, Switzerland). These assays 
measure total circulating (both free and bound) receptor concentra­
tions, since addition of up to 10 ng/ml recombinant TNF-a to plasma 
containing known amounts of sTNFR does not influence these 
assays. The sensitivity of these assays is 100 pg/ml.
Statistical Analysis
Results are expressed as mean ±  SD. The significance of differ­
ences between the various groups of patients was determined by 
using the Mann-Whitney test. Spearman’s rank test was used for 
determining the correlation between cytokine levels and the labora­
tory indexes in the HUS group.
Results
The individual data of cytokine levels in the plasma of 
the HUS patients are displayed in table 2. Only patients
10, 11, 12 and 13 had severe extrarenal manifestations, 
consisting of seizures, loss of consciousness and coma. 
Patient 10 also developed necrosis of the pancreas. The 
latter 3 patients (11-13) died due to cerebral complica­
tions in the acute phase of the disease. No significantly 
increased levels of TNF-a and IL-ip were found in the
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Table 2. P lasm a cytokine levels in  
patients w ith  H U S P a tien t T N F -a IL-1P IL ~6 s T N F R  55 STN FR 75
No. ng/m] ng/m l pg /m l n g /m l ng /m l
1 0.15 < 0 .1 0 < 2 0 3.5 9.3
2 0 .10 < 0 .10 < 2 0 13.2 9.0
3 0.14 < 0 .10 30 45.1 6.4
4 0.15 < 0 .10 < 2 0 38.5 39.8
5 0.15 < 0 .10 < 2 0 17.2 10.9
6 0 .12 < 0 .10 < 2 0 26.4 35.7
7 0.13 < 0 .10 < 2 0 11.1 4.3
8 0.15 < 0 .10 2 0 N M N M
9 0.13 < 0 .10 < 2 0 10.1 20.6
10 0.15 < 0 .10 275 2 2 .0 24.7
11 0.13 < 0 .10 160 28.2 34.0
12 N M N M 2 6 2 32.1 33.2
13 0.14 < 0 .10 4 10 2 0 .2 22.4
P atien ts  1-9 0,13 ± 0 .0 2 < 0 .085 < 3 0 2 0  ±  16++ 1 7 ±  14+
Patien ts  10-13 0.13 ± 0 .0 5 < 0 .10 2 7 7  ± 103** 2 6 ± 6 + 29 ± 6 +
C ontro l (n = 8) 0 .12  ± 0 .02 0.07 ± 0 .0 2 < 2 0 1.4 ±  1 4.2 ±  1
C R F  (n  = 8) 0 .1 4 ± 0 .0 4 Q .0 8 ± 0 .0 5 < 2 0 1 7 ± 6 ++ 2 7 ± 7 +
P lasm a cytokine levels w ere d e te rm in ed  o n  ad m iss io n  in  p a tie n ts  w ith  H U S . P a tien ts  10, 
11 ,12  and  13 had, in con trast w ith  the o th e r  H U S  p a tien ts ,  severe  e x tra re n a l  m an ifes ta tions , 
consisting o f  seizures, loss o f  consciousness, a n d  com a. P a n c re a tic  necrosis  w as also d iag n o ­
sed in pa tien t 10. T he d a ta  are expressed in d iv id u a lly  a n d  as th e  m e a n  ±  S D  o f  the  va rious  
groups. T o  com pare the  da ta  o f  the  d ifferen t g roups o f  p a t ie n ts  a n d  h e a lth y  con tro ls  th e  
M ann-W hitney  test was used.
+ p <  0.05,++ p <  0.001 as co m p ared  to th e  con tro l g roup ; ** p <  0.01 as c o m p a re d  to  H U S  
patien ts  (and the con tro l group). N M  = N o t  enough m a te r ia l  fo r  th e  te s t  availab le .
plasma of patients with HUS as compared to the control 
groups (table 2). Only the 4 patients who had extrarenal 
manifestations (severe form of HUS) had significantly 
elevated levels of IL-6 (277 ±  103 pg/ml), as compared to 
the control group of healthy children, whereas the IL-6 
levels in the plasma of the other HUS patients (<30 pg/ 
ml, mild form of HUS) were not significantly elevated. 
Significantly i ncreased levels of both soluble TNF recep­
tors were found in all HUS patients (sTNFR55 22 ± 12 
ng/ml and sTNFR75 21 ± 13 ng/ml) as compared to the 
control group of healthy children (sTNFR55 1.4 ± 1 ng/ 
ml and sTNFR75 4.2 ±  1 ng/ml). There was no difference 
in the plasma concentrations of sTNFR5 5 and sTNFR7 5 
between the mild and severe forms of HUS. However, 
both sTNFRs were also increased in the plasma of the 
children with chronic renal failure (17 ±  6 ng/ml for 
sTNFR55 and 27 ± 7 ng/ml for the sTNFR75), which 
suggest that renal failure per se, and associated with a 
decrease in clearance causes high levels of sTNFR in the 
plasma.
Plasma levels of TNF-a, IU ip  or sTNFR75 did not 
correlate with hemoglobin, platelets, white blood cell 
count, urea or creatinine. Only sTNFR55 and 11^6 
showed a mild correlation with hemoglobin (r = 0.56 and 
r = 0.52, respectively) and white blood cell count (both r =
0.60, Spearman’s correlation) in the total HUS group.
Discussion
The role of circulating cytokines and soluble TNF 
receptors in the pathogenesis of HUS was investigated in 
this study. No elevated levels of TNF-a, IL-1 (:! and IL-6 
were found in plasma of HUS patients, who had no 
extrarenal manifestations during the disease. In the study 
done by Fitzpatrick et al. [13] in which IL-8 and TNF-a 
were measured in the plasma of 16 HUS patients, only 1 
patient had an elevated concentration of TNF-a in the 
plasma. However, the occurrence of these cytokines in the 
plasma during the initial phase of the disease cannot be 
excluded, because these cytokines have a short half-life
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(less than 1 h) and may therefore no longer be detectable 
in the plasma taken on admission in the hospital. On the 
other hand, Siegler et al. [14] reported that although TNF- 
a  is not detectable in plasma, it is elevated in the urine of 
HUS patients, suggesting that TNF-a may be locally pro­
duced in the kidney and have a local effect in the kidney 
of HUS. Elevated levels of urinary cytokines have also 
been found in other kidney diseases and are believed to 
play a role in local inflammatory and infectious processes 
in the kidney [15]. Evidence for locally produced cyto­
kines in the kidney has also been obtained by immuno- 
staining and in situ hybridization [16] and from in vitro 
experiments with renal cells [17,18]. Evidence for a local 
role of TNF-a in HUS was recently given by Harel et al. 
[19], who gave Shiga-like toxin I to transgenic mice bear­
ing a chloramphenicol acetyltransferase (CAT) reporter 
gene with the TNF-a promoter. When giving Shiga-like 
toxin I to these mice, CAT activity, which reflects the 
degree of the activation of TNF-a synthesis, was induced 
within the kidney, but not in other tissues. Increased pro­
duction of the cytokines TNF-a, IL-1P and IL-6 can also 
be found in the media of cultured human monocytes after 
stimulation with verocytotoxin-1 [20]. A possible role for 
the locally produced TNF-a in the kidney could be to 
increase the susceptibility of the endothelial cells locally 
for verocytotoxin by inducing more verocytotoxin recep­
tors on the cell surface [21].
Elevated levels of IL-6 were only found in the plasma 
of those HUS patients who had extrarenal manifestations, 
consisting of seizures, loss of consciousness, coma and 
pancreatic necrosis. In inflammatory conditions IL-6 is 
synthesized by a wide variety of cell types (macrophages, 
endothelial cells and fibroblasts) upon stimulation with 
TNF-a, IL-1 and other agents. The major effects of IL-6 in 
an infection are the induction of acute-phase proteins in 
hepatocytes and the final differentiation of B cells into 
antibody-producing cells. We have shown before that IL-6 
did not induce the receptor of verocytotoxin on cultured 
human endothelial cells and therefore did not increase the 
susceptibility of the endothelial cells for verocytotoxin, in 
contrast to TNF-a and IL-1 [21]. Although the exact func­
tion of IL-6 in the plasma HUS patients is still unknown 
and the group of HUS patients is small, plasma IL-6 is 
associated in our study with the severity and/or outcome 
of the disease. Closely related to HUS is thrombotic 
thrombocytopenic purpura (TTP), a syndrome which in 
many aspects is familiar to HUS (micro-angiographic 
hemolytic anemia, thrombocytopenia and renal impair­
ment), but in which generalized symptoms (fever and 
neurological complications) are always present. In the
plasma of all the 13 patients of TTP, examined by Wada 
et al. [7], elevated circulating levels of TNF-a, IL-1 (3 and 
IL-6 were found. These data suggest that in patients with 
TTP and in severe cases of HUS, who also develop extra- 
renal manifestations, circulating cytokines may play a role 
in the pathogenesis of the disease.
Recently, two immunologically distinct soluble recep­
tors sTNFR55 and sTNF75 have been identified [22], 
These soluble receptors represent forms of the extracellu­
lar domain of the cell surface receptors for TNF-a and 
studies done in healthy volunteers indicate that TNFa 
itself is involved in the induction of sTNFR release [22, 
23]. Recent studies have shown that in sepsis and in 
malaria elevated levels of sTNFR are present [22,24,25], 
Although both sTNFR were elevated in the plasma of 
HUS patients, they were also elevated in the group of chil­
dren with chronic renal failure. This implies that these 
elevated sTNFR levels cannot only be explained by 
increased activity of TNF-a or by other substances with ; 
proteolytic activity, like elastase, but may be caused by i 
insufficient kidney function. In favor of this hypothesis is 
the recent report by Bemelmans et al. [26], who demon­
strated in a murine model that kidney malfunction in- * 
duces an increase in the amount of sTNFRs in the plas­
ma.
In conclusion, no elevated levels of circulating TNF-a, 
IL-1 (3 and IL 6 were detected in the mild form of HUS. 
On the other hand, elevated levels of IL-6 in the plasma 
were detected in HUS patients who displayed severe 
extrarenal manifestations. Probably locally produced cy­
tokines may be more important in the pathogenesis of 
HUS than the circulating concentration. However, when 
in HUS extrarenal manifestations occur, circulating cyto­
kines may have played or play a role in the pathogenesis. 
Results of elevated circulating sTNFR as shown in this 
study should be carefully interpreted when kidney failure 
exists.
Acknowledgements
W e would like to th a n k  D r. B. R o th  (U niversitä ts-K lin ik , Köln, 
G erm any) and  D r. W . R eitsm a-B ierens (A cadem ic H osp ita l Gro­
ningen., T h e  N etherlands) for supplying us w ith  sera  from  two HUS 
patients. W e th an k  M rs. J . van  d e r  Ven a n d  M rs. J. M ulder for their I 
excellent technical assistance. T h is  s tudy  w as supported  by grant 
C90.1021 from th e  D u tc h  K id n ey  Foundation .
312 van de Kar/Sauerwein/Demacker/Grau/ Cytokines in HUS
van Hinsbergh/Monnens
References
1 Kaplan BS, Cleary TG, Obrig TG: Recent ad- 
vances in understanding the pathogenesis of 
the hemolytic uremic syndromes. Pediatr 
Nephrol 1990;4:276-283.
2 Karmali MA, Petrie M, Lim C, Fleming DC, 
Arbus GS, Lior H: The association between 
idiopathic hemolytic uremic syndrome and in­
fection by verocytotoxin producing Escherichia 
colLJ Infect Dis 1985;151:775-782.
3 Karmali MA: Infection by verocytotoxin-pro- 
ducing Escherichia coli. Clin Microbiol Rev 
1989;2:15-38.
4 Calandra T, Baumgartner JD, Grau GE, Wu 
MM, Lambert PH, Schellekens J, Verhoef J, et 
al: Prognostic values of tumor necrosis factor/ 
cachectin. Interleukin-1, interferon-a, and in- 
terferon-gamma in the serum of patients with 
septic shock. J Infect Dis 1990;161:982-987.
5 Girardin E, Grau GE, Dayer JM, Roux-Lom- 
bard P, the J5 Study Group, Lambert PH: 
Tumor necrosis factor and interleukin-1 in the 
serum of children with severe infectious purpu­
ra. N Engl J Med 1988;319:397-400.
6 Yuang CY, Lin CC, Hwang B, Chiang B: Serial 
changes of serum interleukin-6, interleukin-8, 
and tumor necrosis factor alpha among pa­
tients with Kawasaki disease. J Pediatr 1992; 
121:924-926.
7 Wada H, Kaneko T, Ohiwa M, Tanigawa M, 
Tamaki S, Minami N, Takahashi H, Deguchi 
K, Nakano T; Plasma cytokine levels in throm­
botic thrombocytopenic purpura. Am J Hema- 
tol 1992;40:167-170.
8 Fong FS, De Chaderevian JP, Kaplan BS: Hae- 
molytic-uraemic syndrome: Current concepts 
and management. Pediatr Clin N Am 1982;29: 
835-856.
9 Chart H, van de Kar NCAJ, Tolboom J, Mon- 
nens LAH, Rowe B: Serological detection of 
verocytotoxin-producing Escherichia coli in 
patients with the haemolytic uraemic syn­
drome in Western Europe. Eur J Clin Micro­
biol Infect Dis 1993;12:707-709,
10 van der Meer JWM, Endres S, Lonneman G, 
Cannon JG, Ikejima S, Okusawa S, Gelfand 
LA, Dinarello CA: Concentrations of immuno- 
reactive human tumor necrosis factor-alpha 
produced by human mononuclear cells in vitro.
JLeukoc Biol 1988;43:216-223.
11 Lisi PJ, Chun CW, Koch WA, Endres S, Lonne­
man G, Dinarello CA: Development and use of 
radio-immunoassay for human interleukin-1 p. 
Lymphokine Res 1987;6:229-244.
12 Barrera P, Boerbooms AMTh, Janssen EM, 
Sauerwein RW, Gallati H, Mulder J, et al: Cir­
culating soluble tumor necrosis factor recep­
tors, interleukin-2 receptors, tumor necrosis 
factor-a, and interleukin-6 levels in rheuma­
toid arthritis. Longitudinal evaluation during 
methrottrexate and azathioprinc therapy. Ar­
thritis Rheum 1993;36:1070-1079.
13 Fitzpatrick MM, Shah V, Trompeter RS> DU- 
Ion MJ, Barratt TM: Interleukin-8 and poly- 
morphoneutrophil leucocyte activation in he­
molytic uremic syndrome of childhood. Kid­
ney Int 1993;42:951-956.
14 Siegler RL, Edwin SS, Christofferson RD, 
Mitchell MD: Plasma and urinary cytokines in 
childhood hemolytic urcmic syndrome. J Am 
Soc Nephrol 1991;2:274.
15 Ohta K, Shintani N, Kato E, Yachie A, Seki H, 
Miyawaki T, Taniguchi N: Increased levels of 
urinary interleukin-6 in Kawasaki disease. Eur 
J Pediatr 1993;152:647-649.
16 Yoshioka K, Takemura T, Murakami K, 
Okada M, Yagi K, Miyazato H, Matsushima K, 
Maki S: In situ expression of cytokines in IgA 
nephritis, Kidney Int 1993;44:825-833.
17 Boswell RN, Yard BA, Schrama E, van Es LA, 
Daha MR? van der Woude FJ: Interleukin 6 
production by human proximal tubular epithe­
lial cells in vitro: Analysis of the effccts of inter- 
leukin-la (IL-1 a) and other cytokines. Nephrol 
Dial Transplant 1994;9:599-606.
18 Macica CM, Escalante BA, Conners MS, Fer- 
reri NR: TNF production by the medullary 
thick ascending limb of Hente’s loop. Kidney 
Int 1994;46:113-121.
19 Harel Y, Silva M, Giroir B, Weinberg A, Cleary 
T, Beutler B: A reporter transgene indicates 
renal-specific induction of tumor necrosis fac­
tor (TNF) by Shiga-like toxin: Possible involve­
ment of TN F in hemolytic uremic syndrome. J 
Clin Invest 1993;92:2110-2116.
20 Van Setten PA, Verstraten HGG, van de Heu- 
vel LPWJ, Monnens LAH, Sauerwein RW: Ef­
fects of verocytotoxin- 1 on human monocytes. 
Binding characteristics and induction of cyto­
kine release. Pediatr Nephrol 1993;7:P61.
21 Van de Kar NCAJ, Monnens LAH, Karmali 
MA, van Hinsbergh VWM: Tumor necrosis 
factor and interleukin- 1 induce the expression 
of the verocytotoxin receptor globotriaosylcer- 
amide on human endothelial cells: Implica­
tions for the pathogenesis of the hemolytic ure­
mic syndrome. Blood 1992; 11:2755-2764.
22 Shapiro L, Clark BD, Orencole SF, Poutsiaka 
DD, Granowitz EV, Dinarello CA: Detection 
of tumor necrosis factor soluble p55 in blood 
samples from healthy and endotoxemic hu­
mans. J Infect Dis 1993;167:1344-1350.
23 Lantz M, Malik S, Slevin ML, Olsson I: Infu­
sion of tumor necrosis factor causes an increase 
in circulating TNF-binding protein in humans. 
Cytokines 1990;2:402-406.
24 Van der Poll T, Jansen J, van Leenen D, von 
der Mohlen M, Levi M, ten Cate H, et al: 
Release of soluble receptors for tumor necrosis 
factor in clinical sepsis and experimental endo- 
toxemia. J  InfectDis 1993;168:955-960.
25 Kern P, Hemmer CJ, Gallati H, Neifer S» 
Kremsner P, Dietrich M, et al: Soluble tumor 
necrosis factor receptors correlate with para­
sitemia and disease severity in human malaria. 
J  Infect Dis 1992;166:930-934.
26 Bemelmans MHC, Gouma DJ, Buurman WA: 
Influence of nephrectomie on tumor necrosis 
factor clearance in a murine model. J Immunol 
1993; 150:5:2007-2017.
313
